anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Haemophilia A is a rare genetic disorder estimated to occur in one out of 10,000 live births, characterized by a deficiency in coagulation factor VIII causing impaired haemostasis and prolonged bleeding episodes. Moderate haemophilia, defined as \< 5%, and severe haemophilia, defined as \< 1% of normal factor VIII activity result in frequent and spontaneous bleeds into muscles and joints, commonly the elbows, knees, and ankles. Bleeding into joints can cause acute pain and swelling and can result in reduced joint range of motion, long-term cartilage damage and debilitating haemophilic arthropathy. Early use of prophylaxis with factor VIII replacement is recommended following diagnosis of haemophilia A to maintain joint health and prevent joint destruction. However, despite the use of prophylaxis many patients still experience joint bleeds which may lead to joint deterioration over time. The risk of joint bleeds increases with the amount of time spent below certain FVIII trough levels, e.g. 1, 3 or 5 IU/dL. Thus, there is probably a relation between the intensity of the prophylactic treatment regimen and joint health. Elocta is an extended half-life rFVIII product (EHL rFVIII), with a slower clearance as compared to conventional FVIII products. Treatment with Elocta will therefore provide the treater with a greater flexibility for individualizing prophylaxis as compared to conventional FVIII. Higher trough levels can be reached with Elocta without increasing factor usage or injection frequency. The treater can instead choose to reduce the injection frequency or the factor consumption without lowering trough levels.

Patients may limit their physical activities due to fear of bleeding if they are unaware of their current FVIII level. Patient apps and wearables are now available which allow patients to view their predicted FVIII levels, and capture health-related data (such as bleedings, pain, well-being, physical activity levels etc.). This data can be shared with the treating physician supporting the planning to individualize the patient's factor treatment based on current lifestyle, health status and physical activity levels. Florio, a certified medical device used as part of routine clinical practice, is such an app, and the data output and patient feedback on their activity levels and sense of protection while using Florio will be analysed as exploratory objectives in this study.

The main purpose of this study is to evaluate the effectiveness of Elocta on joint health over a long observation period (48 months). The study will also explore the influence on long term joint health of different Elocta prophylaxis regimens leading to different trough levels and if the extent of patients' physical activity levels can be associated with predicted FVIII levels.
Butyrate, a short-chain fatty acid (SCFA) produced by the fermentation of dietary fibers in the colon, plays a pivotal role in regulating metabolic health, particularly by enhancing insulin sensitivity. Given the rising incidence of metabolic disorders, understanding the factors that influence butyrate production is of significant interest. This study explores the link between salivary amylase activity and butyrate levels in overweight women of reproductive age. Participants were categorized into low (LSA) and high (HSA) salivary amylase activity groups and further divided into two subgroups: one followed a low-starch diet (LS), and the other underwent caloric restriction (CR). We assessed salivary amylase activity and measured serum butyrate concentrations to examine their associations. Our findings showed a significant, though weak, positive correlation (ρ = 0.0486, p < 0.05), suggesting a link between salivary amylase activity and butyrate levels. The statistical significance, despite the weak correlation, implies that this relationship is not random. Moreover, higher baseline butyrate levels were observed in women with elevated salivary amylase activity. Also, women with low salivary amylase activity on a low-starch diet experienced a more pronounced increase in butyrate levels compared to those on caloric restriction. These results suggest that salivary amylase activity and dietary intake interact to influence butyrate production, with potential implications for improving insulin sensitivity and metabolic health. The study underscores the potential of butyrate in enhancing insulin sensitivity and promoting overall metabolic well-being. Further research is necessary to clarify the mechanisms involved and to understand the long-term effects of butyrate on metabolic health across different populations.
PURPOSE: To use a root canal sealing dental filling composition that includes a specific liquid polymerizazble organic monomer and a specific amount of filler to have a desired X-ray impermeability and a desired viscosity, shorten the clinical working time and the curing time and effectively seal the dental root canals. CONSTITUTION: This dental filling composition comprises a filler and a liquid polymerizable organic monomer. The composition is suitable for forming an epoxide-amine addition polymer together with a filler. Particularly, the composition contains a filler, a diepoxide, a primary monoamine and/or a di-secondary diamine. This composition polymerizes to form a thermoplastic polymer suitable for sealing the dental root canals. The content of the filler is 40-85 wt.%. This dental filler is formed by polymerization, has an X-ray impermeability larger than 3 mm/mm Al and a viscosity of <=20,000 cP. When the composition is used, a clinical work can be finished within about 2 hours and the curing time is about 0.5-40 hours.
Gaucher disease is characterized by lysosomal accumulation of glucosylceramide due to impaired glucosylceramide hydrolysis. Type 1 Gaucher disease, the most common form accounts for greater than (\>) 90% of cases and does not involve the central nervous system (CNS). Typical manifestations of Type 1 Gaucher disease include splenomegaly, hepatomegaly, thrombocytopenia, anemia, skeletal pathology and decreased quality of life. The disease manifestations are caused by the accumulations of glucosylceramide (storage material) in Gaucher cells which have infiltrated the spleen and liver as well as other tissue. Eliglustat tartrate is a small molecule developed as an oral therapy which acts to specifically inhibit production of this storage material in Gaucher cells.

This study was designed to determine the efficacy, safety, and pharmacokinetics (PK) of eliglustat tartrate in adult participants (\>16 years) with Gaucher disease Type 1. The study consisted of 2 periods: The Double-Blind Primary Analysis Period (PAP \[Day 1 to Week 39\]) and the Long Term Treatment Period (LTTP/Open-Label Period (post-Week 39 \[Day 1 of the Open-Label Period\] through study completion).
The incidence of moderate to severe pain in cancer patients remains greater than 50%. NIH guidelines recommend the implementation of behavioral cancer pain interventions into patient care. Yet, implementation remains low. Evidence on patient dose-response (i.e., number of sessions, skills), intervention adaption based on initial response, and understanding personal characteristics related to differing dose-response can improve implementation by optimizing behavioral intervention delivery.

This trial is a sequential multiple assignment randomized trial (SMART), that will examine response to differing doses of a behavioral cancer pain intervention (Pain Coping Skills Training \[PCST\]) and subsequent response-based adjustments to doses. Cancer patients with pain (N=327) will initially be randomized to receive either PCST-Full or PCST-Brief. Participants who do not respond (\<30% pain reduction) to their initially assigned intervention will be re-randomized to receive either maintenance (i.e., booster sessions focused on problem solving and skills reinforcement) or an increased level of intervention (i.e., additional sessions and skills). Participants who respond (\> 30% pain reduction) to their initially assigned intervention will be re-randomized to either a maintenance dose or no further treatment. Intervention responses will be (% reduction in pain) will be compared across conditions using a standard two-sided, two-sample t-test. Techniques typically used for SMART studies will be used to compare intervention dosage sequences across PCTS that adjusts to initial dosage based on patient responses. The risk and safety issues in this trial are low and limited to those common to a psychosocial intervention (e.g., loss of confidentiality).
This group will incorporate the KIP protocol, which is a modified physical therapy regimen that is less time-intensive than the gold standard counterpart. Typical structured/skilled physical therapy occurs over the course of 4-8 weeks with 1-2 visits per week to establish improved lower extremity muscle strength, education, and improve gross function. Home exercise programs (HEP) are utilized in tandem with physical therapy visits so that patients are completing interventions 4-5 days per week. Long-term maintenance is generally provided via a refined comprehensive HEP on completion and discharge from formal physical therapy.
INTRODUCTION: Information about condition(s) being present at time of surgery (PATOS) in the American College of Surgeons (ASC) National Surgical Quality Improvement Program (NSQIP) database can influence the postoperative complication rates after liver surgeries. Here, we compare the postoperative complication rates with and without taking condition(s) being PATOS into account.
METHODS: We retrospectively reviewed the ACS NSQIP Participant User Files (PUFs) from 2015 through 2019. We analyzed rates of eight different postoperative complications: superficial surgical site infection (SSI), deep SSI, organ space SSI, pneumonia, urinary tract infection, ventilator, sepsis, and septic shock. In addition, we calculated the percent change in event rates after taking into account whether a condition is PATOS.
RESULTS: Of the 22,463 patients in the ACS NSQIP PUFs for liver surgery, 334 (1.49%) had one or more conditions PATOS. The percentages of patients with PATOS events ranged from 2.03% for superficial SSI to 14.74% for sepsis. For all complications, event rates declined when taking condition(s) PATOS into account. From 2015 through 2019, the observed-to-expected ratios for most complications remained unchanged.
CONCLUSION: Whether a condition is PATOS is important in reporting postoperative complication rates for patients undergoing liver surgery. When taking whether a condition is PATOS into account, we demonstrated an overall decrease in event rates across all eight postoperative complications.
The invention discloses a CTGF (connective tissue growth factor) chimeric vaccine for treating liver fibrosis. The antigenic epitope of the CTGF is inserted into c/e1B cell epitope of hepatitis b virus core antigen to form the CTGF chimeric vaccine which can be assembled into hepatitis B core sample particles. Under the non-adjuvant assistance, the chimeric vaccine can stimulate a body to generate high-valence anti-CTGF neutral antibody. A mouse which is immunized by the chimeric vaccine is obviously relieved in fibrosis degree generated after carbon tetrachloride induction. According to the experimental verification, the CTGF chimeric vaccine can be used for obviously restraining the activation intensity of hepatic stellate cells in the mouse liver, and also can be used for stimulating liver cells to multiply and restraining liver apoptosis. Besides, the TGF-beta 1 and PDGF level in the immunized mouse is obviously reduced, so that the process of liver fibrosis can be relieved in a facilitated manner. According to the results, the CTGF chimeric vaccine can be used for successfully restraining the carbon-tetrachloride-induced mouse liver fibrosis. Therefore, the CTGF chimeric vaccine is expected to be developed into effective means for treating the liver fibrosis.
This proposal aims to determine the effects of explicitly driven or implicitly driven walking modifications on muscle activation patterns and co-contraction post-stroke. This work is significant, as studies have shown that muscle activation patterns after neurologic injury cannot generate walking kinematics comparable to those seen in neurotypical individuals; this finding implies that to attain true walking recovery after neurologic injury, interventions should aim to restore the muscle activations underlying walking behaviors. Here, the researchers first explore muscle activations during walking using biofeedback to guide explicit modification of walking patterns, which is a common approach used in clinical and research interventions for walking retraining. The hypothesis is that explicit walking modifications might be detrimental at a muscle activation level as they engage cortical pathways for voluntary control that have been interrupted by the stroke lesion, resulting in increased muscle co-contraction. Co-contraction hinders true recovery as it impairs the ability to selectively control different segments during walking, resulting in overreliance on compensatory patterns. Researchers will also explore muscle activation patterns during implicit walking modifications. Researchers will use external modifications in the walking environment, mainly split-belt adaptation followed by tied belt walking, to assess if implicit modifications of walking that rely less on cortical neural control are associated with levels of cocontraction comparable to neurotypical controls-an indication that implicitly-mediated modifications could be a more effective approach to restore muscle activation patterns during walking post-stroke. In this study, researchers will assess co-contraction during walking in people post-stroke as the patient reduces asymmetry in step lengths guided by explicit biofeedback (Aim 1) or implicitly following split-belt adaptation and washout (Aim 2). Results from this study will identify the tasks and conditions that can reduce cocontraction to promote restoration of neuromuscular control post-stroke. This proposal will aid develop objective markers of treatment response and functional progress that predict rehabilitation treatment response and enable the tailoring of interventions to the needs, abilities, and resources of the person with disability.
The control-test group (CTG) will initiate the task-oriented training protocol. The task-oriented training protocol will include functional exercise drills, such as sit-up and workout, obstacle course workout, speed-and-direction workout, balance workout, work-up and downhill workout, each tasks performed for eight minutes, with two minutes of rest between them. The difficulty in carrying out the tasks will be progressively adjusted. At all times, individuals will be instructed to contract the pelvic floor musculature. After 20 sessions, the patients will be reassessed and will remain for a period of one month without any intervention, and at the end of this period will be reevaluated again. Next, the CTG group will perform 20 sessions of Pilates exercises.
PURPOSE: To provide a method for detecting IgE and an apparatus and a kit therefor. CONSTITUTION: The presence or amt. of IgE in a sample is determined by a method wherein an allergen is mixed with a pretreatment substance selected from a group consisting of a modifying agent, an org. solvent, a crosslinking agent and a conc. salt soln. to prepare an allergen compsn. (a) and this allergen compsn. is fixed on a solid phase (b) and a sample is brought into contact with this solid phase to form an allergen/allergen specific IgE antibody complex to fix the antigen in the sample on the solid phase (c) and the fixed allergen specific IgE antibody is detected to determine the presence or amt. of IgE in the sample (d). The allergen compsn., an apparatus and a kit used in this method are provided.
This article aims to characterize the language employed in educational and communications materials about STIs, HIV/AIDS and viral hepatitis produced by the Ministry of Health between 2010 and 2019, identifying elements related to health promotion and disease prevention. We conducted an exploratory descriptive study. The materials were selected by performing a systematic search of the Ministry of Health website focusing on the period 2010-2019. The materials were analyzed to determine the educational approaches adopted. The preventive, educational and personal development approaches were identified in 100% (201), 24.87% (50) and 7.96% (16) of the materials, respectively. The radical and popular education for health approaches were not observed. The almost exclusive focus on the preventive approach reveals that promoting changes in individual habits and behavior alone is not sufficient to combat and solve the problem of STIs, HIV/AIDS and viral hepatitis in Brazil.
The invention relates to a preparation method of a traditional Chinese medicine used for treating acute bronchitis. The method is characterized in that the medicine is prepared from the raw materials of, by weight: 15g of white mulberry root-bark, 15g of loquat leaf, 10g of tangerine peel, 10g of asparagus, 5g of perilla leaf, and 500g of water. According to the invention, white mulberry root-bark, loquat leaf, tangerine peel, perilla leaf, and asparagus are cleaned, and soaked for 30min in water. The materials are placed in a vessel such as a casserole, a ceramic pot, or a pottery pot; the materials are decocted twice, and obtained decoctions are mixed, wherein a total amount is 150-200ml. The traditional Chinese medicine is taken when warm. One preparation is taken a day, and is divided in two parts which are respectively taken after breakfast and supper. For a patient with administration difficulty, the preparation can be divided into a plurality of small parts which are taken a plurality of times. A treatment course comprises 5 preparations.
PURPOSE: A polypeptide containing an epitope of fish nodavirus protein is provided to quickly diagnose fish nodavirus disease. CONSTITUTION: A polypeptide of an epitope of fish nodavirus protein contains an amino acid selected from sequence numbers 1-3. A recombinant expression vector contains the polypeptide. A vaccine composition contains the epitope. The vaccine includes a live vaccine, attenuated vaccine, or killed vaccine. A cell inactivated vaccine is a Streptococcus inactivated vaccine. A method for diagnosing fish nodavirus disease comprises a step of reacting an antibody which specifically recognizes the epitope and a sample containing the fish nodavirus; and a step of determining a sample having positive response to the antibody is infected by the fish nodavirus.
AIM: Joint damage due to haemarthrosis can be effectively monitored with point-of care ultrasound using the Haemophilia Early Arthropathy Detection with US (HEAD-US) scoring system. A post hoc comparative analysis of the joint status of patients with severe haemophilia A (HA) or B (HB) was performed.
METHODS: The databases of two observational, cross-sectional studies that recruited patients with HA or HB from 12 Spanish centres were analysed to compare the status of the elbows, knees and ankles in patients with severe disease according to treatment modality. The HEAD-US score was calculated in both studies by the same trained operators.
RESULTS: Overall, 95 HA and 41 HB severe patients were included, with a mean age of 35.2 ± 11.8 and 32.7 ± 14.2 years, respectively. The percentage of patients who received prophylaxis, over on-demand (OD) treatment, was much higher in HA (91.6%) than in HB (65.8%) patients. With a similar number of target joints, the HEAD-US score was zero in 6.3% HA and 22.0% HB patients (p < .01), respectively. The HA population showed significantly worse HEAD-US scores. Whilst osteochondral damage occurred more frequently in patients OD or tertiary prophylaxis, our data suggest that articular damage is less prominent in primary/secondary prophylaxis, regardless of the type of haemophilia. These latter treatment modalities were also associated with a lower prevalence of synovial hypertrophy, particularly in HB patients.
CONCLUSION: This post hoc analysis indicates that joint status seems to be significantly influenced by haemophilia type (HA or HB) and treatment modality in these severe Spanish populations with severe disease. Continuing HEAD-US monitoring for the early detection and management of intra-articular abnormalities, as well as more efficiently tailored therapies should be warranted.
Sepsis is an increasingly worldwide problem; it is currently regarded as a complex life-threatening dysfunction of one or more organs as a result of dysregulated host immune response to infections. The heart is one of the most affected organs, as roughly 10% to 70% of sepsis cases are estimated to turn into sepsis-induced cardiomyopathy (SIC). SIC can be defined as a reversible myocardial dysfunction characterized by dilated ventricles, impaired contractility, and decreased ejection fraction. Mitochondria play a critical role in the normal functioning of cardiac tissues as the heart is highly dependent on its production of adenosine triphosphate (ATP), its damage during SIC includes morphology impairment, mitophagy, biogenesis disequilibrium, electron transport chain disturbance, molecular damage from the actions of pro-inflammatory cytokines and many other different impairments that are major contributing factors to the severity of SIC. Although mitochondria-targeted therapies usage is still inadequate in clinical settings, the preclinical study outcomes promise that the implementation of these therapies may effectively treat SIC. This review summarizes the different therapeutic strategies targeting mitochondria structure, quality, and quantity abnormalities for the treatment of SIC.
The application discloses application of a miR-4670-3p mimic in preparation of a lung cancer treatment drug, and belongs to the technical field of biological medicine. According to the application, research shows that miR-4670-3p is one of the most obvious microRNAs downregulated in lung cancer cells A549. The application also compares the relative expression quantity of miR-4670-3p in lung cancer tissues and paracancerous tissues of lung cancer patients, and discovers that the expression quantity of miR-4670-3p in lung cancer tissues is obviously reduced compared with the paracancerous tissues. Thus, miR-4670-3p has potential targets for diagnosis or treatment of lung cancer. In order to realize the treatment of lung cancer, the miR-4670-3p mimic is designed and synthesized, and the fact that the miR-4670-3p mimic is transfected into lung cancer cells is found to promote apoptosis of the lung cancer cells and inhibit migration of the lung cancer cells, so that the development of lung cancer is inhibited. Therefore, the miR-4670-3p mimic has a prospect of being developed into a novel lung cancer therapeutic drug.
The invention relates to a fusidic acid salt of an antibiotic of the tetracycline series, e.g. tetracycline, chlortetracycline, oxytetracycline and 6-demethylchlortetracycline.  Fusidic acid and the tetracycline are reacted in an organic solvent and the salt is precipitated by the addition of water or a non-solvent, e.g. isopropyl ether.  Alternatively, a salt of fusidic acid, e.g. the sodium salt may be reacted with a salt of tetracycline, e.g. the hydrochloride, in a solvent in which the tetracycline fusidate is insoluble, e.g. water.  The salt has broad spectrum activity and is stable in the presence of serum.  Pharmaceutical compositions comprise a carrier and one or more salts of fusidic acid with a tetracycline antibiotic.  The compositions may be tablets, aromatic powders, granules, emulsions, syrups, injectable solutions or suspensions, suppositories, ovules, intravaginal tablets, ointments, nasal or ear drops, mouth washes and topical dusting powders.